A Study to Evaluate the PK, PD and Safety of CKD-382 in Healthy Subjects

A Randomized, Open-label, Crossover Phase 1 Clinical Trial to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety After Single/Multiple Administration of CKD-382, D860 and D027 in Healthy Subjects

to evaluate the pharmacokinetics, pharmacodynamics and safety after single/multiple administration of CKD-382, D860 and D027 in healthy subjects

A randomized, open-label, crossover phase 1 clinical trial to evaluate the pharmacokinetics, pharmacodynamics and safety after single/multiple administration of CKD-382, D860 and D027 in healthy subjects

Inclusion Criteria:

• Between 19 aged and 50 aged in healthy adult
• Body weight more than 50kg
• BMI more than 18.0 and under 27.0
• Who has negative result on Helicobacter Pylori antibody test

Exclusion Criteria:

• Have clinically significant disease that hepatobiliary system, kidney, nervous system, immune system, respiratory system, endocrine system, hemato-oncology disease, cardiovascular system or mental illness, or a history of mental disease
• Have a gastrointestinal disease history(including surgery) that can effect drug absorption
• Hypersensitivity reaction of clinically significant hypersensitivity reaction in the history of Esomeprazole, additives or benzimidazole family